Investment
Features
FeesSafety
Academy
More
Pluang+

Aker BP undervalued as production set to grow 35% by 2028 with strong infrastructure projects.

Market News
30 Jul 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Aker BP is currently undervalued due to market mispricing its capital cycle and underestimating its growth potential from infrastructure projects like Yggdrasil and Valhall PWP-Fenris. Production is expected to increase by about 35% by 2028, with quick project paybacks of 1–2 years. Despite some execution and regulatory risks, the company’s strong balance sheet, low costs, and steady dividend make it an attractive investment ahead of key catalysts in 2027. The stock trades at deep discounts reflecting current capital expenditures rather than future cash flow generation.

More News

CallTower launches Enterprise Concierge Program for premium support to large organizations.

CallTower launches Enterprise Concierge Program for premium support to large organizations.

CallTower has introduced its Enterprise Concierge Program, a premium service designed to offer personalized, high-touch support for large-scale organizations. The program includes strategic pre-sales planning, dedicated project management, and enhanc...

Others
Bullish
1 hour ago
eSUN launches PLA-Coffee, a sustainable 3D printing filament made from recycled coffee grounds.

eSUN launches PLA-Coffee, a sustainable 3D printing filament made from recycled coffee grounds.

eSUN has introduced PLA-Coffee, a new 3D printing filament combining recycled coffee grounds with biodegradable PLA. This innovation supports sustainability by repurposing organic waste and reducing plastic carbon footprints. The filament offers a un...

Others
Bullish
1 hour ago
AB2 Bio gets $30M from Nippon Shinyaku for U.S. rights to Tadekinig alfa treating rare hyperinflammatory syndrome

AB2 Bio gets $30M from Nippon Shinyaku for U.S. rights to Tadekinig alfa treating rare hyperinflammatory syndrome

AB2 Bio received $30 million from Nippon Shinyaku, which exercised its exclusive U.S. commercialization option for Tadekinig alfa, a treatment for Primary Monogenic IL-18-Driven Hyperinflammatory Syndrome, a rare pediatric disease with no FDA-approve...

Company Fundamentals
Bullish
1 hour ago
Michelin repurchases 193,528 shares at €33.82 each for cancellation on July 30, 2026

Michelin repurchases 193,528 shares at €33.82 each for cancellation on July 30, 2026

On July 30, 2026, Michelin repurchased 193,528 of its own ordinary shares at a weighted average price of €33.82 per share through over-the-counter transactions. The shares bought back are intended for cancellation, which typically reduces the number ...

Company Fundamentals
Neutral
1 hour ago
Michelin repurchases 193,528 shares at €33.82 each for cancellation on July 30, 2026

Michelin repurchases 193,528 shares at €33.82 each for cancellation on July 30, 2026

On July 30, 2026, Michelin executed a share buyback program, purchasing 193,528 ordinary shares at an average price of €33.82 per share. The shares were bought over-the-counter through brokers Natixis, BNP Paribas, and Societe Generale. The purpose o...

Company Fundamentals
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App